Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:36:01.709Z.
Calculation as of: 2026-10-06T17:36:01.709Z.
Quote observation: 2026-10-06T17:35:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6144974dc10feafdeab9fb2faa496306bd94303ba79bd56ccf15562219fd1985
PE RATIO
N/A
Market Cap
$2.11B
PE Ratio
19.82
TTM Avg
21.19
3Y Avg
24.83
5Y Avg
28.15
Market Cap
$2.01B
PE Ratio
6.83
TTM Avg
15.39
3Y Avg
40.25
5Y Avg
40.25
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | $2.06B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.06B | N/A | 33.55 | 33.55 | 33.55 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.04B | N/A | 34.42 | 34.42 | 34.42 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 28.27 | 33.84 | 41.30 | 55.21 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.09B | N/A | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | N/A | 7.63 | 7.63 | 7.63 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 19.82 | 21.19 | 24.83 | 28.15 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 6.83 | 15.39 | 40.25 | 40.25 |
| Pharvaris N.V. (PHVS)vs › | $2.15B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 14.79 | 29.48 | 184.64 | 184.64 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$31.03
Forward EPS (Est.)
$-4.13
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
